Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status

Head and Neck

Volumn 36, Issue 6, 2014, Pages 802-810

  Habbous, Steven ^a   Harland, Luke T G ^a   La Delfa, Anthony ^a   Fadhel, Ehab ^a   Xu, Wei ^a   Liu, Fei Fei ^a,b   Goldstein, David ^a   Waldron, John ^a,b   Huang, Shao Hui ^a,b   O'Sullivan, Brian ^a,b   Liu, Geoffrey ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

alcohol; Charlson Comorbidity Index; head and neck cancer; human papillomavirus; mortality; smoking

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; DEMOGRAPHY; DRINKING BEHAVIOR; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOUTH CANCER; NASOPHARYNX CANCER; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA; WART VIRUS; CANADA; CARCINOMA, SQUAMOUS CELL; FOLLOW UP; HEAD AND NECK NEOPLASMS; INCIDENCE; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; LARYNGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MOUTH NEOPLASMS; NASOPHARYNGEAL NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTOR; VIROLOGY;

AGED; ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; ONTARIO; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 84900474515     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23360     Document Type: Article

References (61)

1. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287.
2. Patel K, Schlundt D, Larson C, Wang H, Brown A, Hargreaves M,. Chronic illness and smoking cessation. Nicotine Tob Res 2008; 11: 933-939.
3. Gimeno-Hernández J, Iglesias-Moreno MC, Gõmez-Serrano M, Carricondo F, Gil-Loyzaga P, Poch-Broto J,. The impact of comorbidity on the survival of patients with laryngeal squamous cell carcinoma. Acta Otolaryngol 2011; 131: 840-846.
4. Sabin SL, Rosenfeld RM, Sundaram K, Har-el G, Lucente FE,. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J 1999; 78:578, 581-582.
5. Peters TT, Langendijk JA, Plaat BE, et al. Co-morbidity and treatment outcomes of elderly pharyngeal cancer patients: a matched control study. Oral Oncol 2011; 47: 1159-1164.
6. Ramroth H, Schoeps A, Rudolph E, et al. Factors predicting survival after diagnosis of laryngeal cancer. Oral Oncol 2011; 47: 1154-1158.
7. Liu CT, Chiu TJ, Huang TL, Chien CY, Fang FM,. Impact of comorbidity on survival for locally advanced head and neck cancer patients treated by radiotherapy or radiotherapy plus chemotherapy. Chang Gung Med J 2010; 33: 283-291.
8. Derks W, de Leeuw RJ, Hordijk GJ,. Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survival. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 92-96.
9. Piccirillo JF,. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology (Williston Park) 1995; 9: 831-836; discussion 841, 845-848.
10. Homma A, Sakashita T, Oridate N, et al. Importance of comorbidity in hypopharyngeal cancer. Head Neck 2010; 32: 148-153.
11. Piccirillo JF, Costas I, Grove L,. A critical appraisal of the use of ICD-9-CM codes to classify comorbidity and complications. J Registry Manag 2003; 30: 117-122.
12. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D,. The measurement of comorbidity by cancer registries. J Registry Manag 2002; 30: 8-14.
13. Charlson M, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
15. Kaplan MH, Feinstein AR,. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27: 387-404.
16. Paleri V, Wight RG, Silver CE, et al. Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 2010; 46: 712-719.
17. Castro MA, Dedivitis RA, Ribeiro KC,. Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2007; 69: 146-152.
18. Deneuve S, Tan HK, Eghiaian A, Temam S,. Management and outcome of head and neck squamous cell carcinomas in obese patients. Oral Oncol 2011; 47: 631-635.
19. Hu M, Ampil F, Clark C, Sonavane K, Caldito G, Nathan CA,. Comorbid predictors of poor response to chemoradiotherapy for laryngeal squamous cell carcinoma. Laryngoscope 2011; 122: 565-571.
20. Dansky Ullmann C, Harlan LC, Shavers VL, Stevens JL,. A population-based study of therapy and survival for patients with head and neck cancer treated in the community. Cancer 2012; 118: 4452-4461.
21. Piccirillo JF, Spitznagel EL Jr, Vermani N, Costas I, Schnitzler M,. Comparison of comorbidity indices for patients with head and neck cancer. Med Care 2004; 42: 482-486.
22. Mell LK, Dignam JJ, Salama JK, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 2010; 28: 15-20.
23. Kallogjeri D, Piccirillo JF, Spitznagel EL Jr, Steyerberg EW,. Comparison of scoring methods for ACE-27: simpler is better. J Geriatr Oncol 2012; 3: 238-245.
24. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 1997; 107 (11 Pt 1): 1469-1475.
25. Wang CY, Lin YS, Tzao CL, et al. Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg 2007; 32: 877-881.
26. Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL,. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002; 112: 1988-1996.
27. Habbous S, Chu KP, Harland LT, et al. Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. Oral Oncol 2013; 49: 407-412.
28. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619.
29. Centers for Disease Control and Prevention. Trends in Current Cigarette Smoking Among High School Students and Adults, United States, 1965-2011. Available at: http://www.cdc.gov/tobacco/data-statistics/tables/trends/cig- smoking/. Accessed: May 4, 2013.
30. Cole L, Polfus L, Peters ES,. Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995-2005. PLoS One 2012; 7: e32657.
31. Holmes JD, Martin RA, Gutta R,. Characteristics of head and neck cancer patients referred to an oral and maxillofacial surgeon in the United States for management. J Oral Maxillofac Surg 2010; 68: 555-561.
32. Patel UA, Lynn-Macrae A, Rosen F, Holloway N, Kern R,. Advanced stage of head and neck cancer at a tertiary-care county hospital. Laryngoscope 2006; 116: 1473-1477.
33. Nygård M, Aagnes B, Bray F, Møller B, Mork J,. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer 2012; 48: 1341-1346.
34. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
35. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2012; 61: 258-261.
36. Simard EP, Ward EM, Siegel R, Jemal A,. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012. [Epub ahead of print]
37. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35: 747-755.
38. Wang XI, Thomas J, Zhang S,. Changing trends in human papillomavirus-associated head and neck squamous cell carcinoma. Ann Diagn Pathol 2012; 16: 7-12.
39. Sethi S, Ali-Fehmi RF, Franceschi S, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer 2012; 131: 1179-1186.
40. Wong K, Huang SH, O'Sullivan B, et al. Point-of-care outcome assessment in the cancer clinic: audit of data quality. Radiother Oncol 2010; 95: 339-343.
41. Bondy SJ, Victor JC, Diemert LM,. Origin and use of the 100 cigarette criterion in tobacco surveys. Tob Control 2009; 18: 317-323.
42. Abel EL, Kruger ML, Friedl J,. How do physicians define "light," "moderate," and "heavy" drinking? Alcohol Clin Exp Res 1998; 22: 979-984.
43. Deleyiannis FW, Thomas DB, Vaughan TL, Davis S,. Alcoholism: Independent predictor of survival in patients with head and neck cancer. J Natl Cancer Inst 1996; 88: 542-549.
44. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221.
45. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM,. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001; 125: 1-9.
46. Dahlstrom KR, Calzada G, Hanby JD, et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer 2013; 119: 81-89.
47. Mizumachi T, Kano S, Sakashita T, et al. Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Int J Clin Oncol 2012. [Epub ahead of print]
48. Hong AM, Martin A, Armstrong BK, et al. Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol 2013; 24: 215-219.
49. Datema FR, Ferrier MB, Vergouwe Y, et al. Update and external validation of a head and neck cancer prognostic model. Head Neck 2012. [Epub ahead of print]
50. Alho OP, Hannula K, Luokkala A, Teppo H, Koivunen P, Kantola S,. Differential prognostic impact of comorbidity in head and neck cancer. Head Neck 2007; 29: 913-918.
51. Hall SF, Groome PA, Irish J, O'Sullivan B,. Towards further understanding of prognostic factors for head and neck cancer patients: the example of hypopharyngeal cancer. Laryngoscope 2009; 119: 696-702.
52. Montero EH, Trufero JM, Romeo JA, Terré FC,. Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy. Tumori 2008; 94: 24-29.
53. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP,. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
54. Ramakrishnan Y, Paleri V, Shah R, Steen IN, Wight RG, Kelly CG,. Comorbidity in nasopharyngeal carcinoma: a preliminary communication on the prevalence, descriptive distribution and impact on outcome. Clin Otolaryngol 2007; 32: 484-488.
55. Sze HC, Ng WT, Chan OS, Shum TC, Chan LL, Lee AW,. Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol 2012; 48: 162-167.
56. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL,. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 2002; 128: 1172-1179.
57. Teppo H, Alho OP,. Comorbidity and diagnostic delay in cancer of the larynx, tongue and pharynx. Oral Oncol 2009; 45: 692-695.
58. Baijal G, Gupta T, Hotwani C, et al. Impact of comorbidity on therapeutic decision-making in head and neck cancer: audit from a comprehensive cancer center in India. Head Neck 2012; 34: 1251-1254.
59. Machtay M, Glatstein E,. " Just another statistic." Oncologist 1998; 3: III-IV.
60. Ji J, Sundguist K, Sundquist J, Hemminki K,. Comparability of cancer identification among death registry, cancer registry and hospital discharge registry. Int J Cancer 2012; 131: 2085-2093.
61. Brotherston DC, Poon I, Le T, et al. Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck 2013; 35: 151-159.